ArticleMolecular imaging and radionuclide therapy2026
Follicular Thyroid Carcinoma with Cavernous Sinus Metastasis and Perineural Spread: A Rare Manifestation of Radioiodine-refractory Disease.
Article in Molecular imaging and radionuclide therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cavernous sinus metastasis from follicular thyroid carcinoma (FTC) is exceedingly rare and typically indicates advanced, radioiodine-refractory disease. We report a 37-year-old man with minimally invasive FTC who was treated with total thyroidectomy, neck dissection, and cumulative radioiodine therapy totaling 720 mCi for persistent iodine-avid disease. Four years later, he developed progressive left-sided palsies of cranial nerves III, IV, and VI. Imaging revealed a cavernous sinus mass with orbital apex extension and perineural spread. Serum thyroglobulin was markedly elevated (>500 ng/mL), whereas diagnostic radioiodine scintigraphy demonstrated no uptake, a finding consistent with dedifferentiated disease. Biopsy confirmed metastatic FTC. The patient received external beam radiotherapy and systemic therapy with lenvatinib; however, the disease progressed, and he died 16 months after the diagnosis of cavernous sinus metastasis. This case highlights the aggressive potential of FTC, the limitations of radioiodine imaging in dedifferentiated disease, and the poor prognosis associated with skull-base metastases despite multimodal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.